[NEWSFLASH]

Button

SpectraCure has its background in Lund University's departments for medical laser applications and physics. The company focuses oncancer treatment with medical devices containing laser light sources and photoreactive drugs, called interstitial photodynamic tumour treatment, abbreviated PDT after 'photodynamic therapy'. The treatment methodology is suitable for internal solid tumours of various kinds, eg prostate, pancreas, but also in other indications such as head and neck cancer.

SpectraCure has its background in Lund University’s departments for medical laser applications and physics. The company focuses oncancer treatment with medical devices containing laser light sources and photoreactive drugs, called interstitial photodynamic tumour treatment, abbreviated PDT after ‘photodynamic therapy’. The treatment methodology is suitable for internal solid tumours of various kinds, eg prostate, pancreas, but also in other indications such as head and neck cancer.

Listing on Nasdaq First North

As of tuesday, december 4th, 2018, the shares of SpectraCure AB (publ) are being traded on Nasdaq First North. The first day on Nasdaq First North was celebrated with traditional bell ringing on the stock exchange.

The need for new medical devices

Every year, about 180,000 people in the United States and 400,000 in the EU are diagnosed with prostate cancer. After radiation therapy, about 60,000 will suffer a recurrence. The need for new treatment methods for these patients is considerable. Such a method is offered by interstitial PDT. Interstitial PDT has the potential to give patients a significantly better quality of life than the treatment options currently offered to patients with recurrent cancer.

SpectraCure’s focus

SpectraCure is focused on cancer treatment with medical devices containing laser light sources and photoreactive drugs, called interstitial photodynamic tumour treatment, abbreviated PDT after ‘photodynamic therapy’. The treatment methodology is suitable for internal solid tumours of various kinds, eg prostate, pancreas, but also in other indications such as head and neck cancer.

Research

The company’s technology is based on over 25 years of scientific research and work in photodynamic therapy (PDT) combined with clinical experience of more than 2,700 PDT treatments of skin tumours at Lund University Hospital.
Several research groups in Europe, the US and Canada have been conducting active research to treat tumours such as prostate cancer with PDT. Several hundred prostate cancer patients have been treated with PDT at various university clinics, with promising results.

Treatment benefits

SpectraCure’s interstitial PDT system with IDOSE® represents a new generation of medical technology systems for treatment planning and dose delivery of laser light, which enables treatment of internal tumours. The system performs dosimetry in real time to avoid overexposure which can lead to damage to healthy tissue. Underexposure which can lead to incomplete treatment is also avoided.